Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kymera Therapeutics, Inc. (KYMR : NSDQ)

• Company Description    Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States. Number of Employees: 188

• Price / Volume Information    Yesterday's Closing Price: $46.20 Daily Weekly Monthly 20 Day Moving Average: 598,355 shares Shares Outstanding: 71.50 (millions) Market Capitalization: $3,303.19 (millions) Beta: 2.17 52 Week High: $53.27 52 Week Low: $19.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.19% 9.18% 12 Week -0.52% -9.68% Year To Date 14.84% 2.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 North Beacon Street 4th Floor - Watertown,MA 02472 USA ph: 857-285-5300 fax: - investors@kymeratx.com http://www.kymeratx.com

• General Corporate Information    Officers Nello Mainolfi - Chief Executive Officer and President Bruce Booth - Chair of the Board of Directors Bruce Jacobs - Chief Financial Officer Felix Baker - Director Jeff Albers - Director Peer Information Kymera Therapeutics, Inc. (CORR.) Kymera Therapeutics, Inc. (RSPI) Kymera Therapeutics, Inc. (CGXP) Kymera Therapeutics, Inc. (BGEN) Kymera Therapeutics, Inc. (GTBP) Kymera Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501575104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 10/30/25 Share - Related Items Shares Outstanding: 71.50 Most Recent Split Date: (:1) Beta: 2.17 Market Capitalization: $3,303.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.73 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 14.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/30/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.10 Price/Cash Flow: - Price / Sales: 73.88 EPS Growth vs. Year Ago Period: -63.79% vs. Previous Quarter: -15.85% Sales Growth vs. Year Ago Period: -55.26% vs. Previous Quarter: -48.07% ROE 06/30/25 - -31.60 03/31/25 - -30.11 12/31/24 - -28.66 ROA 06/30/25 - -27.12 03/31/25 - -25.65 12/31/24 - -24.15 Current Ratio 06/30/25 - 8.32 03/31/25 - 8.49 12/31/24 - 7.53 Quick Ratio 06/30/25 - 8.32 03/31/25 - 8.49 12/31/24 - 7.53 Operating Margin 06/30/25 - -616.03 03/31/25 - -409.07 12/31/24 - -475.57 Net Margin 06/30/25 - -616.03 03/31/25 - -409.07 12/31/24 - -475.57 Pre-Tax Margin 06/30/25 - -616.03 03/31/25 - -409.07 12/31/24 - -475.57 Book Value 06/30/25 - 14.92 03/31/25 - 12.07 12/31/24 - 12.90 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.23 03/31/25 - 0.24 12/31/24 - 0.27

Powered by Zacks Investment Research ©